Zobrazeno 1 - 10
of 100
pro vyhledávání: ''
Autor:
Chang-Xing Lyu, Xiao-Long Fu, Wan-Qin Zeng, Qin Zhang, Lan-ting Gao, Wentao Fang, Lei Zhu, Chang-lu Wang
Publikováno v:
Medical Oncology. 39
BackgroundThere are no optimal regimens for advanced thymic epithelial tumors (TETs) when front-line chemotherapy fails. In this study, we aimed to assess the activity of Bevacizumab in combination with routine chemotherapeutic regimen.MethodsPatient
Autor:
Hayahito Nomi, Kazumasa Komura, Takuya Tsujino, Kohei Taniguchi, Naoki Tanda, Hajime Hirano, Tomohito Tanaka, Haruhito Azuma, Taizo Uchimoto, Yuki Yoshikawa, Yuya Fujiwara, Teruo Inamoto, Yudai Nishimoto, Takeshi Tsutsumi, Kenkichi Saito, Kiyoshi Takahara, Tomoaki Takai, Tomohisa Matsunaga, Atsushi Ichihashi, Naokazu Ibuki, Hirofumi Uehara, Koichiro Minami
Publikováno v:
Medical Oncology. 37
This study aimed to assess the clinical value of C-reactive protein-albumin ratio (CAR) at the initiation of first-line treatment for castration-resistant prostate cancer (CRPC). We identified 221 CRPC patients treated with either androgen-signaling
Autor:
Franco Morelli, Emanuele Naglieri, Nicola Calvani, Laura Orlando, Antonio Gnoni, Vincenzo Emanuele Chiuri, Saverio Cinieri, Palma Fedele
Publikováno v:
Medical Oncology. 36
The aim of our study is to investigate the efficacy of metronomic cyclophosphamide plus low dose of corticosteroids in advanced or metastatic castration-resistant prostate cancer (CRPC) before, between, and after standard chemotherapy, such as doceta
Autor:
Kiminori Sugino, Takenori Niioka, Tomoko Ozeki, Mitsuji Nagahama, Akifumi Suzuki, Masatomo Miura, Koichi Ito
Publikováno v:
Medical Oncology. 36
The aim of this study was to examine the association of lenvatinib-induced adverse events with the trough plasma concentration (C0) in Japanese patients with thyroid cancer. Patients received lenvatinib 24 mg as an initial dose, and sequential dose r
Autor:
Andrea Sendelhofert, Nina Kirstein, Lydia Brandl, Michael Vieth, Antje Menssen, Thomas Kirchner, Jens Neumann
Publikováno v:
Medical Oncology. 36
We have recently identified a positive feedback loop in which c-MYC increases silent information regulator 1 (SIRT1) protein level and activity through transcriptional activation of nicotinamide phosphoribosyltransferase (NAMPT) and NAD+ increase. He
Autor:
Takafumi Suda, Noriyuki Enomoto, Masato Karayama, Hideki Yasui, Kazuki Furuhashi, Hironao Hozumi, Tomoyuki Fujisawa, Yuzo Suzuki, Yutaro Nakamura, Naoki Inui, K. Tanaka
Publikováno v:
Medical Oncology. 35
Aprepitant prevents chemotherapy-induced nausea and vomiting (CINV) in carboplatin-containing chemotherapy. However, it is unknown whether aprepitant salvage therapy after the development of emesis is as effective as adding prophylactic aprepitant to
Publikováno v:
Medical Oncology. 35
The CORRECT trial demonstrated survival benefits with regorafenib monotherapy in patients with treatment-refractory, metastatic colorectal cancer (mCRC). However, the trial's stringent eligibility criteria for regorafenib may limit its external valid
Autor:
Takashi Takeshita, Aiko Sueta, Koichi Suyama, Mototsugu Shimokawa, Yutaka Yamamoto, Hirotaka Iwase, Mai Tomiguchi, Mutsuko Yamamoto-Ibusuki
Publikováno v:
Medical Oncology. 35
Lenvatinib, a multi-tyrosine kinase inhibitor, has been proven to be an effective treatment option for patients with iodine-131-refractory thyroid cancer. Many adverse effects of lenvatinib have been reported; thus, dose reduction is common. However,
Autor:
Marjolaine Gauthier-Loiselle, Wendy Y. Cheng, Ravinder Dhawan, Francis Vekeman, Jennifer Sung, Raymond Miao, Mei Sheng Duh, William Oh
Publikováno v:
Medical Oncology (Northwood, London, England)
It is unclear how treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC) affects real-world patient outcomes. We assessed treatment sequences, patient characteristics and overall survival (OS) in post-docetaxel mCRPC patient
Publikováno v:
Medical Oncology. 34
Previous research has identified disparities between urban and rural cancer care, including clinical trial access. Therefore, we addressed three different questions in patients with metastatic renal cell cancer managed according to national guideline